Modelling the prevalence of age-related macular degeneration (2010-2020) in the UK: Expected impact of anti-vascular endothelial growth factor (VEGF) therapy

British Journal of Ophthalmology

Volumn 95, Issue 10, 2011, Pages 1433-1436

  Minassian, Darwin C ^a   Reidy, Angela ^b   Lightstone, Anita ^c   Desai, Parul ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

^c Royal National Institute of Blind People   (United Kingdom)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLINDNESS; COMPUTER MODEL; COMPUTER SIMULATION; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; ETHNICITY; EXUDATIVE MACULAR DEGENERATION; GENDER; GEOGRAPHIC ATROPHY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; POPULATION DYNAMICS; PREVALENCE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; RISK REDUCTION; SUBRETINAL NEOVASCULARIZATION; UNITED KINGDOM; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BLINDNESS; GEOGRAPHIC ATROPHY; GREAT BRITAIN; HUMANS; INCIDENCE; MIDDLE AGED; MODELS, STATISTICAL; PREVALENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 80053271622     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.195370     Document Type: Article

References (19)

1. Evans JR, Fletcher AE, Wormald RP. Causes of visual impairment in people aged 75 years and older in Britain: an add-on study to the MRC Trial of Assessment and Management of older people in the community. Br J Ophthalmol 2004;88:365-70. (Pubitemid 38333716)
2. Evans JR, Fletcher AE, Wormald RP. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of older people in the community. Ophthalmology 2004;111:513-17. (Pubitemid 38293108)
3. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales, BMC Public Health 2006;6:58.
4. National Institute for Health and Clinical Excellence. Ranibizumab And Pegaptanib For The Treatment Of Age-Related Macular Degeneration: NICE technology appraisal guidance 155, London, 2008.
5. Forrester JW. The impact of feedback control concepts on the management sciences. In: COLLECTED PAPERS OF J.W. FORRESTER, (1975 COLLECTION). Cambridge, MA: Wright-Allen Press, 1960:45-60.
6. Forrester JW. Industrial Dynamics. Cambridge, MA, MIT Press, 1961. reprinted by Productivity Press (1994) and now available from Pegasus Communications, Waltham, MA, USA.
7. Wolstenholme EF. System enquiry: a system dynamics approach. Chichester, UK: John Wiley & Sons, 1990:1-8.
8. Brailsford SC. System dynamics: what's in IT for healthcare simulation modelers. In: Mason SJ, Hill RR, Mönch L, et al. eds. Proceedings of the 2008 Winter Simulation Conference Winter Simulation Conference, Miami, FL, USA, 2008.
9. Augood CA, Vingerling JR, De Jong PT, et al. Prevalence of age-related maculopathy in older Europeans. The European Eye Study (EUREYE). Arch Ophthalmol 2006;124:529-35.
10. The Eye Disease Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
11. Owen CG, Fletcher AE, Donoghue M, et al. How big is the burden of visual loss caused by age-related macular degeneration in the UK? Br J Ophthalmol 2003;87:312-17. (Pubitemid 36307906)
12. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995;102:205-10.
13. Elandt-Johnson RC, Johnson NL. ed. Survival models and data analysis. New York, USA: John Wiley & Sons, 1980.
14. Brown DM, Kaiser PK, Michels M, et al; for the ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
15. Rosenfeld PJ, Brown DM, Heier JS, et al; for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
16. The Royal College of Ophthalmologists Scientific Committee. Ranibizumab: The clinician's guide to commencing, continuing and discontinuing treatment 2008. London, College of Ophthalmologists, 2008.
17. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration: the International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367-74.
18. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050. The potential impact of new treatments. Arch Ophthalmol 2009;127:533-40
19. Smith AF. The growing importance of pharmacoeconomics: the case of age-related macular degeneration. Br J Ophthalmol Published online First: 2010. doi:10.1136/bjo.2010.179945.